Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.52 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.50 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 8/20 | 0.47 |
| ▸ | CTSK | P43235 | 7/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 5/20 | 0.47 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.46 |
| ▸ | ITGAV | P06756 | 1/20 | 0.46 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1214885 | 0.99 | ACE (0.54) | ACEITGB3ITGA2BITGA4ITGB7 | |
| SCHEMBL27406863 | 0.89 | ACE (0.56) | ACEITGB3ITGA2BITGA4ITGB7 | |
| SCHEMBL1217701 | 0.87 | ALOX15 (0.57) | ACEITGB3ITGA2BITGA4ITGB7 | |
| SCHEMBL4801162 | 0.85 | ACE (0.52) | ACEITGB3ITGA2BITGA4ITGB7 | |
| SCHEMBL4801147 | 0.85 | ACE (0.52) | ACEITGB3ITGA2BITGA4ITGB7 | |
| SCHEMBL4801481 | 0.85 | ACE (0.52) | ACEITGB3ITGA2BITGA4ITGB7 | |
| SCHEMBL4739186 | 0.85 | ACE (0.52) | ACEITGB3ITGA2BITGA4ITGB7 | |
| SCHEMBL9888253 | 0.85 | ACE (0.53) | ACEITGB3ITGA2BITGA4ITGB7 | |
| SCHEMBL15253563 | 0.85 | ACE (0.53) | ACEITGB3ITGA2BITGA4ITGB7 | |
| SCHEMBL1069784 | 0.85 | ALDH1A1 (0.44) | ACEITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171789-A1 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. | 2008-07-17 | — | — | US | claimed |
| WO-2008079387-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| US-8324273-B2 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110028544-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20080171789-A1 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. | 2008-07-17 | — | — | US | disclosed |
| WO-2008079387-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080070984-A1 | Compositions and Methods of Treating Schizophrenia | XENOPORT, INC. | 2008-03-20 | — | — | US | disclosed |
| WO-2008034087-A2 | TREATING SCHIZOPHRENIA WITH COMBINATIONS OF LEVODOPA AND AN ANTIPSYCHOTIC AGENT | XENOPORT, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-5580904-A | PENETRATE BLOOD-BRAIN BARRIER | DRUG DELIVERY SYSTEM INSTITUTE, LTD. (JP) | 1996-12-03 | — | — | US | disclosed |
| EP-0614886-B1 | COMPOUND CAPABLE OF INTRACEREBRAL RESIDENCE AND USE THEREOF | DRUG DELIVERY SYSTEM INST LTD (JP) | 1996-10-16 | — | — | EP | disclosed |
| EP-0614886-A1 | COMPOUND CAPABLE OF INTRACEREBRAL RESIDENCE AND USE THEREOF | DRUG DELIVERY SYSTEM INSTITUTE, LTD. (JP) | 1994-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171789-A1 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | COMT, PARK7, DDT | ACE 245/4885ITGB3 4675/4885ITGA2B 4736/4885 |
| US-20080070984-A1 | Compositions and Methods of Treating Schizophrenia | COMT, CHAT, SLC6A3 | ACE 855/4885ITGB3 4637/4885ITGA2B 4657/4885 |
| US-20110028544-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | COMT, PARK7, DDT | ACE 245/4885ITGB3 4675/4885ITGA2B 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.